Asterias Provides 6 Mo. Data Readout From Its AST-OPC1 Phase 1/2a Clinical Trial, Says Results Continue to Demonstrate Favorable Safety Profile, Potential for Durable Cell Engraftment at the Injury Site and Improved Motor Function